Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosaroxin and Cytarabine in Older Adults with Untreated AML
NCT02485353Terminated
- Start
- Oct 2015
- Primary completion
- May 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of vosaroxin in acute myeloid leukemia (AML). Primary endpoint: Rate of Complete Remission at 2 months. Started Oct 2015; status: terminated.
02
Drugs
vosaroxin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02485353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485353.